Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 22Sarcoma 8Breast Neoplasms 5Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Carcinoma, Squamous Cell 3Pancreatic Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Carcinoma, Basal Cell 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sezary Syndrome 1Sarcoma, Kaposi 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Peritoneal Neoplasms 1Paget Disease, Extramammary 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma 1Muir-Torre Syndrome 1Microcystic adnexal carcinoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1

Interventions

Paclitaxel 11Carboplatin 8Radiotherapy 7Letrozole 7Cyclophosphamide 7Trastuzumab 5Chemotherapy, Adjuvant 5Doxorubicin 4Brachytherapy 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4atamestane 3Toremifene 3Tamoxifen 3Radiotherapy, Conformal 3Magnetic Resonance Spectroscopy 3Epirubicin 3Docetaxel 3Cryosurgery 3Cisplatin 3pertuzumab 2Surgical Procedures, Operative 2Radiation 2Lapatinib 2Fulvestrant 2Estrogen Receptor Modulators 2Cryotherapy 2Capecitabine 2Biopsy 2Aromatase Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ductal, Breast × talimogene laherparepvec × Clear all
NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡